ProQR Therapeutics N.V
PRQR
Get informed when a big investor buys or sells
+ FollowMarket Cap$161.2M
Close$
$-0.67
136.8% downside
Current Fair Value
136.8% downsideOvervalued by 136.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $161.20 Million |
|---|---|
| Enterprise Value | $113.36 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.38 |
| Beta | 0.06 |
| Outstanding Shares | 105,362,228 |
Return
| Return on Equity | -121.22% |
|---|---|
| Return on Assets | -46.02% |
| Return on Invested Capital | -72.52% |
Valuation & Multiples
| P/E Ratio | -3.09 |
|---|---|
| PEG | -8.83 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.43 |
| Enterprise Value to EBIT | -2.44 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.89 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$5.19 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$4.58 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 13,700▼ 71.58% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 34.06%▼ 1.21% |
|---|---|
| Total Invested | $56.84M▼ 24.27% |
| Investors Holding | 69▲ 2.00% |
ESG Score
No data
About ProQR Therapeutics N.V
CEO: Daniel De Boer